BioCommerce Week Index companies spent at least $13 billion on 13 M&A deals during the first half of 2006 (see table) — compared with at least $2 billion on 13 deals in last year's first half. But the size and expected upshot of a couple of these transactions on the broader life sciences market are expected to push others to follow suit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.